ServiceUpdated on 1 October 2025
R&D Preclinical Services in Hearing Disorders (Small Molecule to gene) or Joint Research Agreement
About
Cilcare advances hearing disorder R&D with preclinical services (GLP tox, in vivo studies) and serves as an external innovation platform for product development, joint research, and partnerships — covering small molecules to gene therapies.
Type
- Development
- Consulting
Applies to
- Biotech and Lifescience
Organisation
Similar opportunities
Service
CMC Development: From Small Molecules to Gene and Cell Therapy
- Consulting
- Biotech and Lifescience